PL3543240T3 - Inhibitor urat1 i jego stosowanie - Google Patents

Inhibitor urat1 i jego stosowanie

Info

Publication number
PL3543240T3
PL3543240T3 PL17872538.8T PL17872538T PL3543240T3 PL 3543240 T3 PL3543240 T3 PL 3543240T3 PL 17872538 T PL17872538 T PL 17872538T PL 3543240 T3 PL3543240 T3 PL 3543240T3
Authority
PL
Poland
Prior art keywords
urat1 inhibitor
urat1
inhibitor
Prior art date
Application number
PL17872538.8T
Other languages
English (en)
Inventor
Dongfang Shi
Changjin FU
Xi CHENG
Jianghua Zhu
Jie Gu
Original Assignee
Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62172162&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3543240(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. filed Critical Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd.
Priority claimed from PCT/CN2017/111013 external-priority patent/WO2018090921A1/zh
Publication of PL3543240T3 publication Critical patent/PL3543240T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Furan Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL17872538.8T 2016-11-16 2017-11-15 Inhibitor urat1 i jego stosowanie PL3543240T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201611008935 2016-11-16
CN201711115037.9A CN108084186B (zh) 2016-11-16 2017-11-13 Urat1抑制剂及其应用
PCT/CN2017/111013 WO2018090921A1 (zh) 2016-11-16 2017-11-15 Urat1抑制剂及其应用

Publications (1)

Publication Number Publication Date
PL3543240T3 true PL3543240T3 (pl) 2022-10-24

Family

ID=62172162

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17872538.8T PL3543240T3 (pl) 2016-11-16 2017-11-15 Inhibitor urat1 i jego stosowanie

Country Status (18)

Country Link
US (2) USRE50083E1 (pl)
EP (1) EP3543240B1 (pl)
JP (1) JP6925054B2 (pl)
KR (1) KR102263441B1 (pl)
CN (1) CN108084186B (pl)
AU (1) AU2017360465B2 (pl)
CA (1) CA3043942C (pl)
DK (1) DK3543240T3 (pl)
ES (1) ES2923177T3 (pl)
HR (1) HRP20221151T1 (pl)
HU (1) HUE059778T2 (pl)
IL (1) IL266587B2 (pl)
MX (1) MX2019005565A (pl)
MY (1) MY197564A (pl)
PL (1) PL3543240T3 (pl)
PT (1) PT3543240T (pl)
RS (1) RS63572B1 (pl)
TW (1) TWI668213B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6915907B2 (ja) * 2017-05-26 2021-08-04 江▲蘇▼新元素医▲薬▼科技有限公司Ｊｉａｎｇｓｕ Ａｔｏｍ Ｂｉｏｓｃｉｅｎｃｅ Ａｎｄ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 尿酸排泄を促進するｕｒａｔ１阻害剤
US11453674B2 (en) 2018-01-19 2022-09-27 Evopoint Biosciences Co., Ltd. Heterocyclic compound, preparation method and use thereof in medicine
CN108623586B (zh) * 2018-07-16 2021-03-16 广东工业大学 一种咪唑并含氮杂环类化合物的合成方法与应用
CN109432079B (zh) * 2018-09-07 2021-06-22 江苏康缘药业股份有限公司 一种化合物在制备用于痛风的药物中的应用
CN111763180B (zh) * 2019-04-02 2023-06-09 中国医学科学院药物研究所 苯并氮杂环类化合物及其制法和药物用途
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
CN111533718B (zh) * 2020-05-12 2022-05-17 浙江海洲制药有限公司 一种制备苯溴马隆的方法
CN112250688B (zh) * 2020-10-15 2022-11-04 天津科技大学 一类7-氮杂苯并呋喃衍生物及其在抗肿瘤药物中的应用
CN112877295A (zh) * 2021-02-26 2021-06-01 华南理工大学 一种urat1抑制剂体外活性筛选的细胞模型及其构建方法与筛选方法
WO2023221078A1 (en) * 2022-05-20 2023-11-23 Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. Solid forms of a compound for treating or preventing hyperuricemia or gout
CN116189808A (zh) * 2023-01-17 2023-05-30 中国海洋大学 一种hURAT1抑制剂的筛选方法、筛选的化合物及其应用
WO2025223330A1 (zh) * 2024-04-23 2025-10-30 深壶制药(山东)有限公司 吲哚并饱和环类化合物或其衍生物及其应用
CN119241538A (zh) * 2024-09-30 2025-01-03 陕西科技大学 一类三唑并吡啶结构的化合物、合成方法及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117128A (en) * 1976-08-03 1978-09-26 Smithkline Corporation Sulfonyl benzofurans and benzothiophenes having coronary vasodilator activity
NZ193926A (en) 1979-07-06 1984-05-31 Labaz Sanofi Nv 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines
FR2502622A1 (fr) * 1981-03-25 1982-10-01 Synthelabo Derives d'imidazo (1,2-a) pyrimidines, leur preparation et leur application en therapeutique
JPS5973579A (ja) * 1982-10-19 1984-04-25 Kotobuki Seiyaku Kk ベンゾフラン又はベンゾチオフェン誘導体，この化合物を有効成分とする尿酸排泄剤及びその製造方法
US5175184A (en) * 1982-10-19 1992-12-29 Kotobuki Seiyaku Company Limited Benzothiophene derivatives and antihyperuricemia thereof
FR2594438B1 (fr) * 1986-02-14 1990-01-26 Labaz Sanofi Nv Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
GB8820231D0 (en) * 1988-08-25 1988-09-28 Fujisawa Pharmaceutical Co New benzazole compounds processes for preparation thereof & pharmaceutical composition comprising same
CN1308621A (zh) * 1998-05-12 2001-08-15 美国家用产品公司 用于治疗胰岛素抗性和高血糖的苯基氧代－乙酸
US6166069A (en) * 1998-05-12 2000-12-26 American Home Products Corporation Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US20050065208A1 (en) * 2001-07-20 2005-03-24 Bodo Brandts Benzofuranes and their use in the treatment of atrial fibrillation
JP2009227599A (ja) * 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
US8394792B2 (en) 2008-03-31 2013-03-12 C&C Research Laboratories Heterocyclic derivatives
US8748435B2 (en) * 2011-04-01 2014-06-10 Novartis Ag Pyrazolo pyrimidine derivatives
EP2900237A1 (en) * 2012-09-25 2015-08-05 Novartis AG Compounds for use in gastric complication
RU2721844C2 (ru) * 2014-12-29 2020-05-25 Ниппон Кемифар Ко., Лтд. Ингибиторы urat1
US10100015B2 (en) * 2015-03-24 2018-10-16 Shanghai Yingli Pharmaceutical Co., Ltd. Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
CN106065010B (zh) * 2015-04-23 2019-01-01 镇江新元素医药科技有限公司 用于治疗或预防高尿酸血症或痛风的化合物
MX375068B (es) * 2015-09-10 2025-03-06 Jiangsu Atom Bioscience And Pharmaceutical Co Ltd Un grupo de compuestos utilizados para el tratamiento o prevencion de hiperuricemia o gota.
CN114213331B (zh) * 2017-05-26 2024-06-21 江苏新元素医药科技有限公司 一类urat1抑制剂及其应用

Also Published As

Publication number Publication date
AU2017360465A1 (en) 2019-06-06
JP6925054B2 (ja) 2021-08-25
HUE059778T2 (hu) 2022-12-28
EP3543240A4 (en) 2020-05-06
US20200062763A1 (en) 2020-02-27
DK3543240T3 (da) 2022-10-10
EP3543240A1 (en) 2019-09-25
PT3543240T (pt) 2022-08-25
CA3043942C (en) 2021-11-02
EP3543240B1 (en) 2022-07-06
HRP20221151T1 (hr) 2022-11-25
KR102263441B1 (ko) 2021-06-09
TW201819364A (zh) 2018-06-01
CA3043942A1 (en) 2018-05-24
AU2017360465B2 (en) 2021-02-04
USRE50083E1 (en) 2024-08-20
RS63572B1 (sr) 2022-10-31
TWI668213B (zh) 2019-08-11
IL266587A (en) 2019-07-31
IL266587B2 (en) 2023-06-01
ES2923177T3 (es) 2022-09-26
CN108084186A (zh) 2018-05-29
US10875865B2 (en) 2020-12-29
MY197564A (en) 2023-06-23
JP2020503263A (ja) 2020-01-30
MX2019005565A (es) 2019-10-30
KR20190077083A (ko) 2019-07-02
CN108084186B (zh) 2021-06-25

Similar Documents

Publication Publication Date Title
IL270330B (en) Beta-lactamase inhibitors and their uses
IL261606A (en) Inhibitors of transfected menin-mll and methods of use
HUE059778T2 (hu) URAT1-inhibitor és alkalmazása
IL255577B (en) Binding materials - tigit and their uses
IL267291A (en) Actonucleotidase inhibitors and methods of using them
GB201605126D0 (en) Inhibitors and their uses
IL253433A0 (en) Binders - tnfrsf and their uses
HUE051451T2 (hu) A menin-MLL kölcsönhatás inhibitorai
IL264813B (en) 2-oxo-imidazopyridines and their use
IL263949A (en) Complement inhibitors and their uses
EP3336090A4 (en) INHIBITOR OF IRAQ4 AND ITS USE
PL3621694T3 (pl) Inhibitory lrrc33 i ich zastosowanie
SMT202300381T1 (it) Inibitori di lsd1 e loro utilizzi medici
IL267238A (en) The paranase inhibitors and their use
IL254916A0 (en) Inhibitors and their uses
IL265531A (en) N 3 -cyclically substituted thienouraciles and use thereof
IL269836B (en) Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use
ZA201803212B (en) Gelatinase inhibitors and use thereof
IL267243A (en) The paranase inhibitors and their use
IL269843B (en) Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use
IL265617B (en) 1-phenylpropanone compounds and their use
GB2545167B (en) Cloches and use thereof
AU2016903602A0 (en) Inhibitors and uses therefor
GB201505971D0 (en) Inhibitors and their uses
GB201505975D0 (en) Inhibitors and their uses